Navigation Links
Arena Pharma, Geron, Incyte, and Spectrum Pharma Under Microscope

LONDON, July 29, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

On Friday, July 26, 2013, shares of biotech companies ended mostly lower even as the broader market posted gains. The major movers in the industry included Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), Geron Corporation (NASDAQ: GERN), Incyte Corporation (NASDAQ: INCY), and Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI). has released full comprehensive research on ARNA, GERN, INCY, and SPPI. These free technical analyses can be downloaded by signing up at:  

Shares of Arena Pharmaceuticals, Inc. fell sharply on Friday, finishing at $6.86, down 2.14% from its previous trading session's closing price. The company's shares oscillated between $6.83 and $7.01. A total of 3.01 million shares were traded, which is below the daily average volume of 5.84 million. Arena's shares have fallen by 10.91% in the last one month as compared to a loss of 0.03% in the S&P 500. A free technical analysis on ARNA available by signing up at:

Geron Corporation's stock fell sharply on Friday, extending its losses for the week. The company's shares oscillated between $1.38 and $1.44 before ending the day 4.17% lower at $1.38. A total of 260,089 shares were traded, which is below the daily average volume of 994,053. The company's shares fell by 6.76% last week. Nonetheless, the stock has advanced 21.05% in the last three months, outperforming the S&P 500, which has gained 6.91% during the same period. Register today and access free research on GERN at:

Shares of Incyte Corporation edged lower on Friday, reversing some of their recent gains. The company's shares oscillated between $22.74 and $23.46 before finishing the session 0.17% lower at $23.34. A total of 553,069 shares were traded, which is below the daily average volume of 1.18 million. Incyte's shares have gained 2.14% in the last three trading sessions and 6.09% in the last one month, outperforming the S&P 500 during the respective periods. Moreover, the stock is currently trading above its 50-day and 200-day moving averages. The free report on INCY can be downloaded by signing up now at:

Spectrum Pharmaceuticals, Inc.'s stock fluctuated between gains and losses on Friday before finishing the day flat. The company's shares oscillated between $8.26 and $8.50 before closing the day flat at $8.39. A total of 439,651 shares were traded, which is below the daily average volume of 917,988. Spectrum Pharmaceuticals' shares fell by 1.76% last week. In the last one month, however, the stock has outperformed the broader market, gaining 12.47% as compared to an advance of 5.31% in the S&P 500. A free report on SPPI can be accessed by registering at:


  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at
  5. For any urgent concerns or inquires, please contact us at
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE AAA Research Reports
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. SynCardia Total Artificial Heart Bridges Former Semi-Pro Arena Football Player to Heart Transplant
2. Todays Research on Incyte and Arena Pharma: Biotech Stocks Up on Drug Approvals
3. New Competitive Arena Emerges for Pharmaceutical Companies in Healthcares Changing Payment Landscape, Finds PwC Health Research Institute Study
4. Todays Technical View: AstraZeneca, GlaxoSmithKline, Keryx Biopharma, and Raptor Pharma
5. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
6. MannKind, Ariad Pharma, Ziopharm Oncology, Galena Biopharma, and Novavax Under StockCalls Microscope
7. Amarin, Pharmacyclics, Anthera Pharma, Star Scientific, and Impax Laboratories Under StockCalls Microscope
8. Air Products to Feature Medical and Industrial Grade Gas Solutions for Pharma, Biotech, and Life Science Applications at Mid-Atlantic Bio Conference
9. ARMGO Pharma, Inc. announces data which supports its Rycal program as a novel approach for the treatment of stress-induced cognitive disorders
10. Enox Biopharma, Inc. Grants TTA LTD License To Wound Care Applications
11. Enox Biopharma, Inc. Will Present at IN360 Investment in Innovation Conference
Post Your Comments:
(Date:10/9/2015)... Pa. and ROCKVILLE, Md. ... Inc. ("ITI"), a privately-held biotechnology company developing next ... announced that it has entered into an exclusive ... LAMP-vax products for the treatment or prevention of ... execution of the agreement, Immunomic Therapeutics will receive ...
(Date:10/9/2015)... ... October 09, 2015 , ... Leading microbial genomics startup uBiome today ... understand the relationship between weight management and the microbiome. The study uses the ResearchKit ... using an iPhone app. , The uBiome app is available as a free download ...
(Date:10/8/2015)... -- Genetic testing for mutations beyond those currently recommended in ... at risk of having a child with cystic fibrosis, ... American Society of Human Genetics (ASHG) Annual Meeting, which ... . The study is one of four that ... presenting at the conference this week demonstrating the clinical ...
(Date:10/8/2015)... BALTIMORE, Maryland , October 8, 2015 /PRNewswire/ ... .   --> Goldman ... specializing in the small cap and microcap sectors, ... sponsored research report on PharmaCyte Biotech, Inc. (OTCQB ... company focused on developing and preparing treatments for ...
Breaking Biology Technology:
... (, ) announced today the publication ... written and edited by Richard S. Lord and ... by Bralley and Lord, Laboratory,Evaluations in Molecular Medicine, ... arm of Metametrix Inc., a leader in nutritional ...
... Exemplary Work ... of Oncology ... winner,and finalists of its 2008 Extraordinary Healer Award for Oncology ... Annual,Congress. Ortho Biotech Products, L. P. sponsored the award, which ...
... Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) announced today that ... study of intravenous REOLYSIN(R) in patients with,sarcomas metastatic ... Society of,Clinical Oncology (ASCO) website at ... . The abstract is entitled "A Phase II,Study ...
Cached Biology Technology:
(Date:10/5/2015)... October 5, 2015 ... for NXT-ID, Inc. (NASDAQ: NXTD ), a biometric ... --> ) releases the ... NXTD ), a biometric authentication company focused on ... Technology Group ( ) releases the ...
(Date:10/1/2015)... , Oct. 1, 2015  Biometrics includes ... analysing human body characteristics, such as fingerprints, eye ... purposes. Adoption of biometrics technology has been constantly ... the last five years. In addition to the ... is fingerprint recognition, other means of biometric authentication ...
(Date:9/30/2015)... GARDENS, Fla. , Sept. 30, 2015  The ... this month issued another key ruling in favor of ... determination that Korean fingerprint scanner company Suprema and its ... Act of 1930, a trade provision that declares it ... import trade, by infringing two of Crossmatch,s patents, the ...
Breaking Biology News(10 mins):
... blended biodiesel fuels purchased from small-scale retailers, researchers at ... the blends do not contain the advertised amount of ... sampled pure biodiesel and blends from more than a ... listed as 20 percent biodiesel (commonly known as B20), ...
... complex has multiple causes. It,s sometimes hard to classify ... than any other disease -- an estimated $690 million ... a team of Kansas State University researchers is stepping ... Department of Agriculture, the team is analyzing data from ...
... and wisest mythology allude to the snake as a ... legend surrounding this proverbial predator may not be based ... Virginia recently discovered, the common fear of snakes is ... were capable of surviving the dangers of an uncivilized ...
Cached Biology News:
Human ABCG2 MAb (Clone 5D3)...
... purified Formulation: 50mM Tris-HCl, pH ... 0.2mM PMSF, 1mM benzamidine, 0.1% ... PP2A1 (Protein Phosphatase 2A1) partially ... sulfate precipitation, QSepharose,amino-hexyl agarose, Superdex ...
... The Beacon 2000 One-Step FP Standardization ... high and low fluorescence polarization values ... of the Beacon 2000 System. It ... polarization values generated by their instrument ...
Although each Beacon 2000 System includes one preinstalled sample chamber (size specified at time of order), optional chambers are available and easily retrofit by the user....
Biology Products: